The FDA has granted Breakthrough Device Designation to a closed-loop spinal cord stimulator developed by Saluda Medical — a device that continuously reads electrical signals from the dorsal column and automatically adjusts its own stimulation parameters in real time. The designation, which fast-tracks review for devices addressing serious conditions without adequate alternatives, signals regulatory confidence that the technology represents a meaningful advance over conventional spinal cord stimulation for chronic pain.
The Problem With Open-Loop Stimulation
Conventional spinal cord stimulators deliver fixed electrical pulses on a programmed schedule. Because the distance between the electrode and the spinal cord changes with body position, the effective stimulation varies throughout the day — patients feel too much stimulation lying down and too little standing. Closed-loop systems solve this by reading the evoked compound action potential (ECAP) from the spinal cord after each pulse and adjusting the next pulse’s amplitude within milliseconds.
Device Snapshot
- →FDA Breakthrough Device designation granted — accelerated review pathway
- →ECAP sensing — reads spinal nerve response after every pulse, adjusts in <1ms
- →3× improvement in consistent paresthesia coverage vs open-loop in Phase III trial
- →50M+ people globally live with chronic back pain — the primary target indication
What This Means For The Future
Closed-loop neural devices represent a fundamental shift in bioelectronic medicine — from delivering fixed electrical doses to engaging in a continuous dialogue with the nervous system. The same ECAP-sensing architecture being validated for pain could eventually be applied to bladder control, depression, and epilepsy. Breakthrough Device Designation doesn’t guarantee approval, but it commits FDA reviewers to regular meetings with the sponsor and a compressed review timeline.
Source: FDA Breakthrough Device Designation Database · Saluda Medical press release